-+ 0.00%
-+ 0.00%
-+ 0.00%

Chardan Capital Maintains Buy on Immuneering, Maintains $13 Price Target

Benzinga·06/18/2025 11:02:10
Listen to the news
Chardan Capital analyst Geulah Livshits maintains Immuneering (NASDAQ:IMRX) with a Buy and maintains $13 price target.